PK Assays for Antibody–Drug Conjugates: Case Study with Ado-Trastuzumab Emtansine
- 3 May 2013
- journal article
- Published by Taylor & Francis in Bioanalysis
- Vol. 5 (9) , 1025-1040
Abstract
Antibody-drug conjugates (ADCs) combine the characteristics of large-molecule biologics and small-molecule drugs and are heterogeneous mixtures that can biotransform in vivo, resulting in additional complexity. ADC bioanalytical strategies require novel analytical methods, as well as existing large- and small-molecule methods. Because ADCs in late-stage clinical development are relatively new, regulatory guidelines and standard industry best practices for developing strategies for bioanalytical PK assays are still being established. A PK assay strategy was developed that included comprehensive novel reagent and assay characterization approaches for the ADC ado-trastuzumab emtansine (T-DM1). The bioanalytical strategy was successfully applied to the drug development of T-DM1 and ensured that key analytes were accurately measured in support of nonclinical and clinical development.Keywords
This publication has 29 references indexed in Scilit:
- Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugatesNature Biotechnology, 2012
- Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancerCancer Chemotherapy and Pharmacology, 2012
- In VitroandIn VivoResponses of Advanced Prostate Tumors to PSMA ADC, an Auristatin-Conjugated Antibody to Prostate-Specific Membrane AntigenMolecular Cancer Therapeutics, 2011
- A novel pathway for maytansinoid release from thioether linked antibody–drug conjugates (ADCs) under oxidative conditionsChemical Communications, 2011
- Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody–drug conjugate SGN-75British Journal of Cancer, 2010
- Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast CancerJournal of Clinical Oncology, 2010
- Anti-CD22-MCC-DM1 and MC-MMAF Conjugates: Impact of Assay Format on Pharmacokinetic Parameters DeterminationBioconjugate Chemistry, 2008
- Arming antibodies for cancer therapyCurrent Opinion in Pharmacology, 2005
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neuOncogeneScience, 1987
- Enzyme-linked immunosorbent assay (ELISA) quantitative assay of immunoglobulin GImmunochemistry, 1971